Capricor Therapeutics Inc
CAPR7.320USD
-0.580-7.35%
交易中 （美東）報價延遲15分鐘
334.34M總市值
虧損本益比TTM
關於 Capricor Therapeutics Inc 公司
Capricor Therapeutics, Inc. 是一家生物技術公司，致力於開發轉化細胞和外泌體療法，用於治療和預防罕見疾病。該公司的項目專注於開發和商業化由心臟球衍生細胞 (CDC) 組成的細胞治療技術，用於治療杜氏肌營養不良症 (DMD)。其主要候選產品 CAP-1002 是一種同種異體心臟衍生細胞療法。CAP-1002 正在進行 3 期臨牀開發，用於治療杜氏肌營養不良症 (DMD)。CAP-1002 具有專門針對肌營養不良症和心臟病的免疫調節、抗纖維化和再生作用。該公司利用其外泌體技術，使用其 StealthX 平臺進行臨牀前開發，專注於疫苗學、寡核苷酸、蛋白質和小分子療法的靶向遞送領域，以治療和預防多種疾病。
公司簡介
公司代碼CAPR
公司名稱Capricor Therapeutics Inc
上市日期Jun 04, 2002
CEODr. Linda Marban, Ph.D.
員工數量160
證券類型Ordinary Share
年結日Jun 04
公司地址10865 Road to the Cure
城市SAN DIEGO
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編92121
電話13103583200
網址https://capricor.com/
公司代碼CAPR
上市日期Jun 04, 2002
CEODr. Linda Marban, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Linda Marban, Ph.D.
Dr. Linda Marban, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
212.02K
+6.26%
Mr. David B. Musket
Mr. David B. Musket
Independent Director
Independent Director
88.79K
--
Mr. Anthony Bergmann
Mr. Anthony Bergmann
Chief Financial Officer
Chief Financial Officer
8.22K
+43.68%
Michael Binks
Michael Binks
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Frank I. Litvack, M.D.
Dr. Frank I. Litvack, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. George W. Dunbar, Jr.
Mr. George W. Dunbar, Jr.
Independent Director
Independent Director
--
--
Dr. Paul Auwaerter, M.D.
Dr. Paul Auwaerter, M.D.
Independent Director
Independent Director
--
--
Ms. Karimah Es Sabar
Ms. Karimah Es Sabar
Independent Director
Independent Director
--
--
Ms. Karen G. Krasney, J.D.
Ms. Karen G. Krasney, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
--
--
Dr. Philip J. (Phil) Gotwals, Ph.D.
Dr. Philip J. (Phil) Gotwals, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Linda Marban, Ph.D.
Dr. Linda Marban, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
212.02K
+6.26%
Mr. David B. Musket
Mr. David B. Musket
Independent Director
Independent Director
88.79K
--
Mr. Anthony Bergmann
Mr. Anthony Bergmann
Chief Financial Officer
Chief Financial Officer
8.22K
+43.68%
Michael Binks
Michael Binks
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Frank I. Litvack, M.D.
Dr. Frank I. Litvack, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. George W. Dunbar, Jr.
Mr. George W. Dunbar, Jr.
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 6月7日 週六
更新時間: 6月7日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Nippon Shinyaku Co Ltd
15.51%
BlackRock Institutional Trust Company, N.A.
5.89%
The Vanguard Group, Inc.
5.04%
Farallon Capital Management, L.L.C.
4.92%
State Street Global Advisors (US)
4.03%
Other
64.60%
持股股東
持股股東
佔比
Nippon Shinyaku Co Ltd
15.51%
BlackRock Institutional Trust Company, N.A.
5.89%
The Vanguard Group, Inc.
5.04%
Farallon Capital Management, L.L.C.
4.92%
State Street Global Advisors (US)
4.03%
Other
64.60%
股東類型
持股股東
佔比
Investment Advisor
16.88%
Corporation
15.51%
Investment Advisor/Hedge Fund
10.46%
Hedge Fund
9.89%
Research Firm
3.18%
Individual Investor
1.28%
Bank and Trust
0.30%
Pension Fund
0.22%
Venture Capital
0.21%
Other
42.06%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
249
26.45M
57.87%
+1.42M
2025Q1
248
26.31M
57.59%
+1.55M
2024Q4
207
25.12M
55.44%
+10.37M
2024Q3
154
16.01M
37.60%
+3.34M
2024Q2
126
9.07M
28.24%
-1.39M
2024Q1
98
7.40M
24.60%
-337.42K
2023Q4
80
6.78M
23.62%
+312.08K
2023Q3
81
6.27M
24.30%
+2.56M
2023Q2
82
3.34M
13.02%
-283.03K
2023Q1
82
3.13M
12.44%
-2.22M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Nippon Shinyaku Co Ltd
7.09M
15.51%
+4.94M
+230.41%
Sep 20, 2024
BlackRock Institutional Trust Company, N.A.
2.69M
5.89%
-69.04K
-2.50%
Mar 31, 2025
The Vanguard Group, Inc.
2.26M
4.94%
-12.79K
-0.56%
Mar 31, 2025
Farallon Capital Management, L.L.C.
2.25M
4.92%
--
--
Mar 31, 2025
State Street Global Advisors (US)
1.84M
4.03%
-365.57K
-16.55%
Mar 31, 2025
Geode Capital Management, L.L.C.
901.38K
1.97%
+21.91K
+2.49%
Mar 31, 2025
Morgan Stanley & Co. LLC
735.10K
1.61%
+164.73K
+28.88%
Mar 31, 2025
Woodline Partners LP
729.32K
1.6%
+99.38K
+15.78%
Mar 31, 2025
Citadel Advisors LLC
415.95K
0.91%
+150.71K
+56.82%
Mar 31, 2025
UBS Financial Services, Inc.
393.34K
0.86%
+270.52K
+220.26%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Neuroscience and Healthcare ETF
0.98%
Virtus LifeSci Biotech Clinical Trials ETF
0.64%
Simplify Propel Opportunities ETF
0.59%
ALPS Medical Breakthroughs ETF
0.31%
Hypatia Women CEO ETF
0.15%
SPDR S&P Biotech ETF
0.12%
iShares Micro-Cap ETF
0.09%
Direxion Daily S&P Biotech Bull 3X Shares
0.07%
Vanguard US Momentum Factor ETF
0.07%
iShares Russell 2000 Growth ETF
0.03%
查看更多
iShares Neuroscience and Healthcare ETF
佔比0.98%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.64%
Simplify Propel Opportunities ETF
佔比0.59%
ALPS Medical Breakthroughs ETF
佔比0.31%
Hypatia Women CEO ETF
佔比0.15%
SPDR S&P Biotech ETF
佔比0.12%
iShares Micro-Cap ETF
佔比0.09%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.07%
Vanguard US Momentum Factor ETF
佔比0.07%
iShares Russell 2000 Growth ETF
佔比0.03%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
